IKT Stock Gets Increased EPS Forecast from HC Wainwright

Inhibikase Therapeutics, Inc. (NASDAQ:IKT – Free Report) – Analysts at HC Wainwright upped their Q1 2027 earnings estimates for shares of Inhibikase Therapeutics in a research note issued on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.12) per share for the quarter, up from their previous forecast of ($0.13). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.42) EPS.

Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01.

IKT has been the subject of several other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Thursday, October 15th. Wall Street Zen raised Inhibikase Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Chardan Capital reissued a “neutral” rating and issued a $1.50 price objective on shares of Inhibikase Therapeutics in a research report on Thursday, November 12th. Three research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $4.75.

View Our Latest Analysis on IKT

Inhibikase Therapeutics Stock Down 4.6%

NASDAQ IKT opened at $1.45 on Monday. The firm’s fifty day simple moving average is $1.87 and its two-hundred day simple moving average is $1.93. Inhibikase Therapeutics has a 12-month low of $1.40 and a 12-month high of $2.61.

Hedge Funds Weigh In On Inhibikase Therapeutics

Several hedge funds have recently modified their holdings of IKT. Abel Hall LLC boosted its stake in Inhibikase Therapeutics by 15.0% in the 3rd quarter. Abel Hall LLC now owns 53,311 shares of the company’s stock worth $110,000 after purchasing an additional 6,959 shares in the last quarter. Spark Investment Management LLC purchased a new stake in Inhibikase Therapeutics during the 2nd quarter worth approximately $31,000. Renaissance Technologies LLC purchased a new stake in Inhibikase Therapeutics during the 1st quarter worth approximately $28,000. Seven Fleet Capital Management LP increased its stake in Inhibikase Therapeutics by 6.5% during the 2nd quarter. Seven Fleet Capital Management LP now owns 346,900 shares of the company’s stock valued at $704,000 after purchasing an additional 21,300 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in Inhibikase Therapeutics during the 1st quarter valued at approximately $48,000. Institutional investors and hedge funds own 3.81% of the company’s stock.

Inhibikase Therapeutics Company Profile

(Get Free Report)

Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson’s disease and other neurodegenerative disorders. The company’s research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration. Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson’s disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.

Recommended Stories

Earnings History and Estimates for Inhibikase Therapeutics (NASDAQ:IKT)

Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.